CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab

Simone de Vries Lentsch, Linda Al-Hassany, Michel Dominique Ferrari, Gisela Marie Terwindt, Antoinette MaassenVanDenBrink

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)
Original languageEnglish
Pages (from-to)911-912
Number of pages2
JournalJournal of neurology, neurosurgery, and psychiatry
Issue number8
Publication statusPublished - 1 Aug 2022

Bibliographical note

Funding Information:
This work was supported by grants of the Dutch Research Council (NWO; Spinoza Award 2009 to MDF and VICI grant 09150181910040 to AMVB).

Funding Information:
AMVB reports consultancy or industry support from Novartis, Lilly and Teva, who are all three companies that are marketing CGRP (receptor) monoclonal antibodies, and independent support from the Dutch Research Council and the Dutch Heart & Brain Foundations. GT reports consultancy support from Novartis, Lilly, Teva (see above), Allergan and independent support from Dutch Research Council, and the Dutch Heart & Brain Foundations. SdVL, LA-H and MDF have no conflict of interest to declare.

Cite this